Skeletal effects of low-dose cyclosporin A in aged male rats:: Lack of relationship to serum testosterone levels

被引:25
作者
Erben, RG
Stangassinger, M
Gärtner, R
机构
[1] Univ Munich, Inst Physiol Physiol Chem & Anim Nutr, Munich, Germany
[2] Univ Munich, Med Klin Innenstadt, Dept Endocrinol, D-8000 Munich, Germany
关键词
D O I
10.1359/jbmr.1998.13.1.79
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to investigate the skeletal effects of cyclosporin A (CsA) in a dose range relevant to clinical medicine in lumbar vertebral cancellous bone of aged male rats and to correlate these effects with possible changes in serum testosterone levels. Thirty-one 18-month-old male Wistar rats were divided into four weight-matched groups and subcutaneously injected with either 0, 1, 3, or 5 mg of CsA/kg of body, weight three times per week After 4 weeks of treatment, all rats were killed after in vivo fluorochrome labelling and the first lumbar vertebrae analysed by quantitative histomorphometry, Serum was analysed for total calcium, creatinine, alkaline phosphatase, osteocalcin, parathyroid hormone, total testosterone, and CsA levels, CsA administration resulted in a dose-dependent increase in serum osteocalcin levels and in histomorphometric indices of cancellous bone turnover in the axial skeleton. Furthermore, CsA-treated rats showed a deterioration of vertebral cancellous bone structure with increased discontinuity of the trabecular bone network due to trabecular plate perforations. Serum testosterone levels were not significantly changed by CsA treatment and were uncorrelated to all biochemical or histomorphometric indices of bone turnover. We conclude that the 4-week administration of CsA at doses that are close to those used in transplantation patients induced high turnover osteopenia in the axial skeleton of aged, 18-month-old male rats, and that these effects were likely not mediated by changes in serum testosterone levels.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 34 条
[1]  
Baron R.A., 1983, BONE HISTOMORPHOMETR, P13
[2]   The role of testosterone in cyclosporine-induced osteopenia [J].
Bowman, AR ;
Sass, DA ;
Dissanayake, IR ;
Ma, YF ;
Liang, H ;
Yuan, Z ;
Jee, WSS ;
Epstein, S .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (04) :607-615
[3]   T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia [J].
Buchinsky, FJ ;
Ma, YF ;
Mann, GN ;
Rucinski, B ;
Bryer, HP ;
Romero, DF ;
Jee, WSS ;
Epstein, S .
ENDOCRINOLOGY, 1996, 137 (06) :2278-2285
[4]   Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis [J].
Canalis, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3441-3447
[5]  
CAVALLINI L, 1990, VIRCHOWS ARCH B, V58, P215
[6]  
DELPOZO E, 1995, BONE, V16, pS271, DOI 10.1016/S8756-3282(95)80097-2
[7]   LACK OF EVIDENCE THAT CYCLOSPORINE TREATMENT IMPAIRS CALCIUM-PHOSPHORUS HOMEOSTASIS AND BONE REMODELING IN NORMOCALCEMIC LONG-TERM RENAL-TRANSPLANT RECIPIENTS [J].
DUMOULIN, G ;
HORY, B ;
NGUYEN, NU ;
HENRIET, MT ;
BRESSON, C ;
REGNARD, J ;
SAINTHILLIER, Y .
TRANSPLANTATION, 1995, 59 (12) :1690-1694
[8]  
EPSTEIN S, 1994, J BONE MINER RES, V9, P557
[9]  
Epstein S, 1996, J BONE MINER RES, V11, P1
[10]   1,25 DIHYDROXYVITAMIN-D3 MODIFIES CYCLOSPORINE-INDUCED BONE LOSS [J].
EPSTEIN, S ;
SCHLOSBERG, M ;
FALLON, M ;
THOMAS, S ;
MOVSOWITZ, C ;
ISMAIL, F .
CALCIFIED TISSUE INTERNATIONAL, 1990, 47 (03) :152-157